Biomarkers

One of the greatest challenges in Parkinson's disease is that diagnosis often occurs after significant neurological changes have already taken place. Researchers now believe the disease may begin years—or even decades—before the motor symptoms that typically trigger clinical evaluation. By the time symptoms appear, most patients have lost 60% to 80% or more of the dopamine-producing cells in the substantia nigra. This growing understanding has intensified the search for reliable biomarkers that could improve diagnosis, monitor disease progression, guide clinical trial recruitment, and support the development of new therapies.

When Angela Haupt, a health and wellness editor at Time Magazine, had nearly two dozen vials of her blood drawn for a health startup, she received eight pages of clinical notes analyzing 105 personalized biomarkers. Did she receive valuable insights predictive of her future health, or an overload of indecipherable data? The answer is debatable. It may depend on who you ask, who is reading the information, and for what purpose. What is certain is that the use of biomarkers in the healthcare industry is expected to grow exponentially.